Results 261 to 270 of about 3,868,024 (353)

Sources of Information and Pharmacists' Knowledge Regarding Rare Diseases and Orphan Drugs: Cross-Sectional Study In Serbia [PDF]

open access: bronze, 2014
Jasmina Arsić   +4 more
openalex   +1 more source

Orphan drugs: Indian perspective

open access: yesIndian Journal of Pharmacology, 2017
Harish Kumar, Bikash Medhi, Phulen Sarma
openaire   +3 more sources

Mesenchymal Stromal Cell Secretome and Its Key Bioactive Metabolites Induce Long‐Term Neuroprotection After Traumatic Brain Injury in Mice

open access: yesAdvanced Science, Volume 12, Issue 29, August 7, 2025.
Pischiutta F and coworkers identify prostaglandins and kynurenine as key mediators of the mesenchymal stromal cells‐derived secretome's neuroprotective effects. A synthetic cocktail composed of these factors promotes long‐term functional recovery, reduces brain structural damage, and modulates neuroinflammation after traumatic brain injury, supporting ...
Francesca Pischiutta   +24 more
wiley   +1 more source

Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography

open access: yesArthritis &Rheumatology, Volume 77, Issue 8, Page 1015-1025, August 2025.
Objective This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin   +11 more
wiley   +1 more source

Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?

open access: yesCancer Medicine, Volume 14, Issue 15, August 2025.
This study presents a real‐world analysis of patients with advanced solid tumors discussed at the Molecular Tumor Board (MTB) of University Hospital Brno, Czech Republic, between 2021 and 2025. Comprehensive genomic profiling guided matched therapies in 17.4% of cases, with a clinical benefit (PFS2/PFS1 ≥ 1.3) observed in 41.4% of evaluable patients ...
Michal Eid   +19 more
wiley   +1 more source

Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey [PDF]

open access: bronze, 2015
Nick Dragojlovic   +5 more
openalex   +1 more source

FDA Approval of Orphan Drug Indications for Pediatric Patients, 2011-2023.

open access: yesJAMA Pediatr
Kakkilaya A, Shahzad M, Bourgeois FT.
europepmc   +1 more source

Home - About - Disclaimer - Privacy